Patients First: Cost–Benefit Considerations in HCV Therapy

Mark S. Sulkowski, MD

Patients First: Cost–Benefit Considerations in HCV Therapy

Hello folks, with all this controversy over the high price of Gilead's Sovaldi, it was refreshing, and informative to watch a video presentation where the focus is on the HCV patient, and not only on drug cost.

This month Clinical Care Options launched a new 35 minute video module addressing the cost issue of new hepatitis C drugs. Interestingly enough, in comparison to the high cost of overall care needed to manage HCV patients, it appears these new drugs are more cost effective. But we all knew that, didn't we.

The program is hosted by Nancy Reau, MD, and Mark S. Sulkowski, MD,. from Johns Hopkins.

Topics include

• Benefits of achieving SVR with HCV therapy
• Impact of HCV on the healthcare system
• Considering immediate cost vs deferred savings
• Using cost per SVR to determine value of therapy
• Importance of selecting the best therapy first 

*Free registration is required to view the program.

Clinical Focus: Clinical Outcomes and Cost–Benefit Considerations in HCV Therapy
Nancy Reau, MD, and Mark S. Sulkowski, MD, provide a clinical perspective on the debate over economic aspects of HCV therapy and explore whether new therapies increase or decrease overall HCV patient care costs.

Stay well, and safe.

Tina